September 25, 2025Cancer Immunology Research

Abstract B001: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade

View Full Paper

Ask AI

Bookmark

Authors

OAOluwatoyosi AdewunmiThe University of Texas MD Anderson Cancer Center ADArielle G. DessensThe University of Texas MD Anderson Cancer Center ASAloukick Kumar SinghThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Preclinical analysis reveals PD-1 inhibitors recruit protective CD8 T cells in tumors, suggesting improved efficacy while mitigating autoimmune toxicities.

Key Points

PD-1 inhibitors increase recently recruited CD8 T cells in tumors, while maintaining a less exhausted phenotype.
The recruitment dynamics of CD8 T cells show significant differences between tumor sites and those experiencing adverse events.
Current methods allow tracking of T cell entry into tissues over time, revealing insights on immune responses to checkpoint inhibitors.
The dual role of T cell recruitment emphasizes the need for targeted approaches to enhance anti-tumor immunity and reduce autoimmune risks.

Cite This Study

Adewunmi et al. (2025) studied this question.

synapsesocial.com/papers/68d5dabfddad3c16d4636ff7 https://doi.org/10.1158/2326-6074.cimm25-b001

View Full Paper

Ask AI

Bookmark

Implication

Preclinical analysis reveals PD-1 inhibitors recruit protective CD8 T cells in tumors, suggesting improved efficacy while mitigating autoimmune toxicities.